Ozanimod for adult patients with relapsing remitting multiple sclerosis
SMC
Record ID 32018001091
English
Authors' objectives:
To assess clinical and cost effectiveness.
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/ozanimod-zeposia-full-smc2309/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/ozanimod-zeposia-full-smc2309/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Multiple Sclerosis, Relapsing-Remitting
- Biological Products
- Sphingosine 1 Phosphate Receptor Modulators
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.